These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

398 related articles for article (PubMed ID: 21767441)

  • 21. A randomized, double-blind, duloxetine-referenced study comparing efficacy and tolerability of 2 fixed doses of vortioxetine in the acute treatment of adults with MDD.
    Mahableshwarkar AR; Jacobsen PL; Chen Y; Serenko M; Trivedi MH
    Psychopharmacology (Berl); 2015 Jun; 232(12):2061-70. PubMed ID: 25575488
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The safety and tolerability of vortioxetine: Analysis of data from randomized placebo-controlled trials and open-label extension studies.
    Baldwin DS; Chrones L; Florea I; Nielsen R; Nomikos GG; Palo W; Reines E
    J Psychopharmacol; 2016 Mar; 30(3):242-52. PubMed ID: 26864543
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Randomized, 8-week, double-blind, placebo-controlled trial of vortioxetine in Japanese adults with major depressive disorder, followed by a 52-week open-label extension trial.
    Inoue T; Nishimura A; Sasai K; Kitagawa T
    Psychiatry Clin Neurosci; 2018 Feb; 72(2):103-115. PubMed ID: 29160598
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: A 6-month randomized controlled trial.
    Gelenberg AJ; Lydiard RB; Rudolph RL; Aguiar L; Haskins JT; Salinas E
    JAMA; 2000 Jun; 283(23):3082-8. PubMed ID: 10865302
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies.
    Tourian KA; Padmanabhan SK; Groark J; Brisard C; Farrington D
    Clin Ther; 2009 Jun; 31 Pt 1():1405-23. PubMed ID: 19698901
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lisdexamfetamine dimesylate augmentation for adults with major depressive disorder and inadequate response to antidepressant monotherapy: Results from 2 phase 3, multicenter, randomized, double-blind, placebo-controlled studies.
    Richards C; McIntyre RS; Weisler R; Sambunaris A; Brawman-Mintzer O; Gao J; Geibel B; Dauphin M; Madhoo M
    J Affect Disord; 2016 Dec; 206():151-160. PubMed ID: 27474961
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Once-daily venlafaxine extended release (XR) and venlafaxine immediate release (IR) in outpatients with major depression. Venlafaxine XR 208 Study Group.
    Cunningham LA
    Ann Clin Psychiatry; 1997 Sep; 9(3):157-64. PubMed ID: 9339881
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lu-AA21004, a multimodal serotonergic agent, for the potential treatment of depression and anxiety.
    Adell A
    IDrugs; 2010 Dec; 13(12):900-10. PubMed ID: 21154150
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lu AA21004, a multimodal psychotropic agent, in the prevention of relapse in adult patients with generalized anxiety disorder.
    Baldwin DS; Loft H; Florea I
    Int Clin Psychopharmacol; 2012 Jul; 27(4):197-207. PubMed ID: 22475889
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Vortioxetine for the treatment of depression.
    Pearce EF; Murphy JA
    Ann Pharmacother; 2014 Jun; 48(6):758-65. PubMed ID: 24676550
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Vortioxetine in the treatment of adult patients with major depressive disorder: a meta-analysis of randomized double-blind controlled trials.
    Berhan A; Barker A
    BMC Psychiatry; 2014 Sep; 14():276. PubMed ID: 25260373
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Vortioxetine (Lu AA21004) 5 mg in generalized anxiety disorder: results of an 8-week randomized, double-blind, placebo-controlled clinical trial in the United States.
    Rothschild AJ; Mahableshwarkar AR; Jacobsen P; Yan M; Sheehan DV
    Eur Neuropsychopharmacol; 2012 Dec; 22(12):858-66. PubMed ID: 22901736
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lu AA21004, a novel multimodal antidepressant, produces regionally selective increases of multiple neurotransmitters--a rat microdialysis and electrophysiology study.
    Pehrson AL; Cremers T; Bétry C; van der Hart MG; Jørgensen L; Madsen M; Haddjeri N; Ebert B; Sanchez C
    Eur Neuropsychopharmacol; 2013 Feb; 23(2):133-45. PubMed ID: 22612991
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A double-blind, randomized, placebo-controlled trial of once-daily venlafaxine extended release (XR) and fluoxetine for the treatment of depression.
    Rudolph RL; Feiger AD
    J Affect Disord; 1999 Dec; 56(2-3):171-81. PubMed ID: 10701474
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Current and Future Perspectives on the Major Depressive Disorder: Focus on the New Multimodal Antidepressant Vortioxetine.
    Orsolini L; Tomasetti C; Valchera A; Iasevoli F; Buonaguro EF; Fornaro M; Fiengo ALC; Martinotti G; Vellante F; Matarazzo I; Vecchiotti R; Perna G; Di Nicola M; Carano A; Di Bartolomeis A; De Giannantonio M; De Berardis D
    CNS Neurol Disord Drug Targets; 2017; 16(1):65-92. PubMed ID: 27781949
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant treatment: a multicentre, randomized, double-blind, placebo-controlled study.
    El-Khalili N; Joyce M; Atkinson S; Buynak RJ; Datto C; Lindgren P; Eriksson H
    Int J Neuropsychopharmacol; 2010 Aug; 13(7):917-32. PubMed ID: 20175941
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A randomised, double-blind study in adults with major depressive disorder with an inadequate response to a single course of selective serotonin reuptake inhibitor or serotonin-noradrenaline reuptake inhibitor treatment switched to vortioxetine or agomelatine.
    Montgomery SA; Nielsen RZ; Poulsen LH; Häggström L
    Hum Psychopharmacol; 2014 Sep; 29(5):470-82. PubMed ID: 25087600
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study.
    Berman RM; Marcus RN; Swanink R; McQuade RD; Carson WH; Corey-Lisle PK; Khan A
    J Clin Psychiatry; 2007 Jun; 68(6):843-53. PubMed ID: 17592907
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy, safety, and tolerability of vortioxetine for the treatment of major depressive disorder in patients aged 55 years or older.
    Nomikos GG; Tomori D; Zhong W; Affinito J; Palo W
    CNS Spectr; 2017 Aug; 22(4):348-362. PubMed ID: 27869048
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and safety of vilazodone in major depressive disorder: a randomized, double-blind, placebo-controlled trial.
    Croft HA; Pomara N; Gommoll C; Chen D; Nunez R; Mathews M
    J Clin Psychiatry; 2014 Nov; 75(11):e1291-8. PubMed ID: 25470094
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.